AR065800A1 - Metodo para tratar el dolor mediado por los receptores canabinoides perifericos (cb2) - Google Patents

Metodo para tratar el dolor mediado por los receptores canabinoides perifericos (cb2)

Info

Publication number
AR065800A1
AR065800A1 ARP080101149A ARP080101149A AR065800A1 AR 065800 A1 AR065800 A1 AR 065800A1 AR P080101149 A ARP080101149 A AR P080101149A AR P080101149 A ARP080101149 A AR P080101149A AR 065800 A1 AR065800 A1 AR 065800A1
Authority
AR
Argentina
Prior art keywords
hydroxy
halogen
positions
optionally substituted
hexahydro
Prior art date
Application number
ARP080101149A
Other languages
English (en)
Spanish (es)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39766329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065800(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR065800A1 publication Critical patent/AR065800A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP080101149A 2007-03-21 2008-03-19 Metodo para tratar el dolor mediado por los receptores canabinoides perifericos (cb2) AR065800A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89601407P 2007-03-21 2007-03-21

Publications (1)

Publication Number Publication Date
AR065800A1 true AR065800A1 (es) 2009-07-01

Family

ID=39766329

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101149A AR065800A1 (es) 2007-03-21 2008-03-19 Metodo para tratar el dolor mediado por los receptores canabinoides perifericos (cb2)

Country Status (14)

Country Link
US (1) US20080234347A1 (https=)
EP (1) EP2139326A4 (https=)
JP (1) JP2010522181A (https=)
KR (1) KR20090120499A (https=)
CN (1) CN101677556A (https=)
AR (1) AR065800A1 (https=)
AU (1) AU2008229264A1 (https=)
CA (1) CA2681381A1 (https=)
CL (1) CL2008000827A1 (https=)
MX (1) MX2009010162A (https=)
PE (1) PE20090062A1 (https=)
TW (1) TW200901972A (https=)
UY (1) UY30973A1 (https=)
WO (1) WO2008115671A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101787116B1 (ko) * 2009-01-28 2017-10-18 케러 테라퓨틱스, 인코포레이티드 바이시클릭 피라졸로-헤테로사이클
EP3541371A4 (en) * 2017-11-15 2020-07-22 Panag Pharma Inc. METHODS OF TREATING INTERSTITIAL CYSTITIS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1698335A4 (en) * 2003-12-26 2007-08-01 Ono Pharmaceutical Co AGENT FOR PREVENTING AND / OR TREATING DISEASES INVOLVING A MITOCHONDRIAL BENZODIAZEPINE RECEPTOR
TW200602324A (en) * 2004-03-24 2006-01-16 Janssen Pharmaceutica Nv Tetrahydro-indazole cannabinoid modulators cross reference to related applications
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
PL1937259T3 (pl) * 2005-09-23 2012-04-30 Janssen Pharmaceutica Nv Heksahydrocykloheptapirazolowe modulatory receptora kanabinoidowego

Also Published As

Publication number Publication date
TW200901972A (en) 2009-01-16
CA2681381A1 (en) 2008-09-25
US20080234347A1 (en) 2008-09-25
MX2009010162A (es) 2009-10-12
CN101677556A (zh) 2010-03-24
JP2010522181A (ja) 2010-07-01
PE20090062A1 (es) 2009-01-26
EP2139326A4 (en) 2011-06-15
WO2008115671A1 (en) 2008-09-25
CL2008000827A1 (es) 2008-09-26
AU2008229264A1 (en) 2008-09-25
UY30973A1 (es) 2008-09-30
EP2139326A1 (en) 2010-01-06
KR20090120499A (ko) 2009-11-24

Similar Documents

Publication Publication Date Title
PE20242113A1 (es) Compuestos de quinolina como inhibidores de kras
MA34732B1 (fr) Spiro-oxindoles antagonistes de mdm2
GT200900294A (es) Compuestos amino-heterocíclicos
MX2017007489A (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos.
TR201802944T4 (tr) İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇
EA201000808A1 (ru) Индольные соединения и способы лечения висцеральной боли
CL2011003052A1 (es) Compuesto 8-(2,4-dimetoxi-pirimidin-5-il)-1-(1-etil-3-metil-1h-pirazol-4-il)-3-metil-1,3-dihidro-imidazo[4,5-c]quinolin-2-ona; su composicion farmaceutica; util en el tratamiento de enfermedades dependientes de la cinasa de lipido y/o de proteina, en el tratamiento de enfermedades proliferativas, tales como tumores y carcinomas de cerebro, riñon, higado, entre otras.
WO2014110086A3 (en) 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof
EA201400358A1 (ru) Замещенные n-[1-циано-2-(фенил)этил]-2-азабицикло[2.2.1]гептан-3-карбоксамидные ингибиторы катепсина с
AR093532A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CR20190433A (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
EP2254411A4 (en) COMPLEMENT INHIBITORS AS A THERAPEUTIC FOR THE TREATMENT OF CANCER
BR112014015923A2 (pt) formulações de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metano-sulfoniletil]-4-acetilaminoisoindolina-1,3-diona
AR109108A1 (es) Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2
NZ603108A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MX378932B (es) Triazoles sustituidos y métodos relacionados a estos.
AR065800A1 (es) Metodo para tratar el dolor mediado por los receptores canabinoides perifericos (cb2)
AR131110A2 (es) Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmática
EP4591940A3 (en) Deoxy- cytidine derivatives for use in cancer therapies
AR065799A1 (es) Moduladores cannabinoides hexahidrocicloheptapirazol
JP2015534990A5 (https=)
ZA202006573B (en) Liquid depot for non-invasive sustained delivery of agents to the eye
PE20210416A1 (es) Inhibidores de ckd8/19
RU2018143006A (ru) Способ органосохраняющего лечения уротелиального рака лоханки почки

Legal Events

Date Code Title Description
FA Abandonment or withdrawal